Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Ebert

Showing results (191-200 of 225) with videos related to

Pageof 23
Sort By:
Pharmacoeconomics|February 4, 2026
Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and SpainJonathan Briody, Ian S Miller, James F O'Mahony, et al.
Oncology Research and Treatment|September 5, 2025
Structured magnetic resonance imaging assessment improves diagnosis of pathological complete response in rectal cancer after neoadjuvant chemoradiationMoying Li, Tobias Dieckmann, Florian Herrle, et al.
Zeitschrift Fur Gastroenterologie|March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]M P Ebert, C Auernhammer, K Caca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2013
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)H Fensterer, C Schade-Brittinger, H-H Müller, et al.
Cell & Bioscience|March 15, 2026
Semi-automated isolation of parenchymal and non-parenchymal liver cells from mice and humans with enhanced stellate cell fractionAnne Dropmann, Bedair Dewidar, Kerry Gould, et al.
Journal of Geriatric Oncology|August 3, 2024
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA studyMoying Li, Nadja M Meindl-Beinker, Martin Maenz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb studyB Schultheis, D Reuter, M P Ebert, et al.
Ebiomedicine|July 14, 2019
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor AElke Burgermeister, Francesca Battaglin, Fagr Eladly, et al.
The American Journal of Pathology|October 11, 2023
Insulin Determines Transforming Growth Factor β Effects on Hepatocyte Nuclear Factor 4α Transcription in HepatocytesRilu Feng, Chenhao Tong, Tao Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 29, 2024
A randomized trial of behavioral interventions yielding sustained reductions in distracted drivingJeffrey P Ebert, Ruiying A Xiong, Neda Khan, et al.
Pageof 23

Showing results (191-200 of 225) with videos related to

Sort By:
Pageof 23
Pharmacoeconomics|February 4, 2026
Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and SpainJonathan Briody, Ian S Miller, James F O'Mahony, et al.
Oncology Research and Treatment|September 5, 2025
Structured magnetic resonance imaging assessment improves diagnosis of pathological complete response in rectal cancer after neoadjuvant chemoradiationMoying Li, Tobias Dieckmann, Florian Herrle, et al.
Zeitschrift Fur Gastroenterologie|March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]M P Ebert, C Auernhammer, K Caca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2013
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)H Fensterer, C Schade-Brittinger, H-H Müller, et al.
Cell & Bioscience|March 15, 2026
Semi-automated isolation of parenchymal and non-parenchymal liver cells from mice and humans with enhanced stellate cell fractionAnne Dropmann, Bedair Dewidar, Kerry Gould, et al.
Journal of Geriatric Oncology|August 3, 2024
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA studyMoying Li, Nadja M Meindl-Beinker, Martin Maenz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb studyB Schultheis, D Reuter, M P Ebert, et al.
Ebiomedicine|July 14, 2019
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor AElke Burgermeister, Francesca Battaglin, Fagr Eladly, et al.
The American Journal of Pathology|October 11, 2023
Insulin Determines Transforming Growth Factor β Effects on Hepatocyte Nuclear Factor 4α Transcription in HepatocytesRilu Feng, Chenhao Tong, Tao Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 29, 2024
A randomized trial of behavioral interventions yielding sustained reductions in distracted drivingJeffrey P Ebert, Ruiying A Xiong, Neda Khan, et al.
Pageof 23